Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment-Reference-Cited by-同舟云学术

Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment

Published:2021-10 Issue: Volume: Page:
ISSN:0161-6420
Container-title:Ophthalmology
language:en
Short-container-title:Ophthalmology

Author:

Douglas Raymond S.,Kahaly George J.,Ugradar Shoaib,Elflein Heike,Ponto Katharina A.,Fowler Brian T.,Dailey Roger,Harris Gerald J.,Schiffman Jade,Tang Rosa^ORCID,Wester Sara,Jain Amy Patel,Marcocci Claudio,Marinò Michele,Antonelli Alessandro^ORCID,Eckstein Anja,Führer-Sakel Dagmar,Salvi Mario^ORCID,Sile Saba,Francis-Sedlak Megan,Holt Robert J.,Smith Terry J.

Publisher

Elsevier BV

Subject

Ophthalmology

Reference30 articles.

1. The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota;Bartley;Trans Am Ophthalmol Soc,1994

2. Assessing quality of life in Australian patients with Graves’ ophthalmopathy;Park;Br J Ophthalmol,2004

3. Quality of life in a German Graves orbitopathy population;Ponto;Am J Ophthalmol,2011

4. What are the psychosocial outcomes of treatment for thyroid eye disease? A systematic review;Wickwar;Thyroid,2014

5. Public health relevance of Graves’ orbitopathy;Ponto;J Clin Endocrinol Metab,2013

Cited by 61 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Mini-review on New Developments in Nanocarriers and Polymers for Ophthalmic Drug Delivery Strategies;Current Drug Delivery;2024-05

2. Long-Term Follow-Up of a Case of Severe Hyperglycemia Requiring Hospitalization after Third Dose of Teprotumumab: A Case Report;Case Reports in Ophthalmology;2024-02-05

3. Teprotumumab for Thyroid Eye Disease-related Strabismus;Ophthalmic Plastic & Reconstructive Surgery;2024-02-02

4. Disease Modulation Versus Modification: A Call for Revised Outcome Metrics in the Treatment of Thyroid Eye Disease;Ophthalmic Plastic & Reconstructive Surgery;2024-01-25

5. Data mining and analysis of adverse event signals associated with teprotumumab using the Food and Drug Administration adverse event reporting system database;International Journal of Clinical Pharmacy;2024-01-20